Europe
EMD Serono, a unit of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) had approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive disease (SPMS).
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
Galapagos NV published its annual report for the financial year 2018.
The SAB, composed of international experts in the field of allergy immunotherapy, acknowledged the clinical benefits of gp-ASIT+™ and confirmed the interest of a follow-up study to enhance the future market positioning and differentiation of the compound.
The Lead Discovery Center has won Dortmund’s Business Prize, awarded yearly by the Wirtschaftsförderung and the Sparkasse Dortmund.
Annual Report 2018 is available for download on the Pharming website
Gilead Sciences and Belgium-based Galapagos NV reported positive late-stage results from its FINCH 1 and FINCH 3 rheumatoid arthritis studies.
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1
amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, will present a poster on the mode of action of its lead candidate AMC303 at the upcoming American Association for Cancer Research Annual Meeting.
PRESS RELEASES